Olanzapine augmentation in elderly patients with treatment-resistant major depression: An open trial [Tedaviye dirençli majör depresyonu olan yaşli hastalarda olanzapin ekleme tedavisi: Bir açik çalişma]

Basit Öğe Kaydı
dc.contributor.authorMirsal H.
dc.contributor.authorKalyoncu A.
dc.contributor.authorPektaş Ö.
dc.contributor.authorTan D.
dc.contributor.authorBeyazyürek M.
dc.date.accessioned2024-07-12T21:51:39Z
dc.date.available2024-07-12T21:51:39Z
dc.date.issued2003en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractObjective: Multiple therapeutic approaches are available for the treatment of patients who are not responding to standard antidepressant medications. One of them is drug augmentation. The effectiveness of olanzapine augmentation treatment for refractory or treatment-resistant major depression in patients over 60 years of age was studied. Methods: An 6-week open label study was conducted in 23 patients with recurrent major depression without psychotic features. The refractory or treatment-resistant depression was defined retrospectively by history of failure to respond to antidepressants at an acceptable therapeutic doses and duration and, patients were required to score >20 on the 17-item Hamilton Depression Rating Scale (HDRS). Subjects were assigned to two phases of treatment; optimization with antidepressant monotherapy at two weeks, and then augmentation with olanzapine (10mg/day). Results: The study subjects were 15 female patients (65.2%), 8 male patients (34.8%). The mean age of the study group was 65.5 years (SD=5.6). The mean HDRS score before and after optimization was 25.6 (SD=3.1) and 25.2 (SD=5.6), respectively. The mean HDRS score at the end of one week of olanzapine augmentation treatment was 15.8 (SD=1.9), at the end of 4 weeks 12.6 (SD=2.1) and at the end of 6 weeks 11.3 (SD=2.7). The differences between the means were statistically significant (p<0.001). HDRS scores for 65.2% of patients (n=15) at the end of 6 weeks of olanzapine augmentation treatment decreased more than 50%. Conclusions: Olanzapine plus standart antidepressant treatment demonstrated superior efficacy for treating refractory or treatment-resistant depression in over 60 age patients.en_US
dc.identifier.endpage5en_US
dc.identifier.issn1017-7833
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-0037364112en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12415/8298
dc.identifier.volume13en_US
dc.indekslendigikaynakScopus
dc.language.isotren_US
dc.relation.ispartofKlinik Psikofarmakoloji Bultenien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY02139
dc.subjectAugmentationen_US
dc.subjectElderly peopleen_US
dc.subjectOlanzapineen_US
dc.subjectTreatment-resistant major depressionen_US
dc.titleOlanzapine augmentation in elderly patients with treatment-resistant major depression: An open trial [Tedaviye dirençli majör depresyonu olan yaşli hastalarda olanzapin ekleme tedavisi: Bir açik çalişma]en_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu